Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Systematic review: does endocrine therapy prolong survival in patients with prostate cancer?

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Robotic versus laparoscopic urological surgery: incidence of reoperation and complications

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Successful extraction of sperm cells after autologous bone marrow transplant: a case report

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. The prognostic impact of incidental prostate cancer following radical cystoprostatectomy: a nationwide analysis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. National incidence and survival of patients with non-invasive papillary urothelial carcinoma: a Danish population study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Implantation of the argus sling in a hard-to-treat patient group with urinary stress incontinence

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Active Surveillance Versus Radical Prostatectomy in Favorable-risk Localized Prostate Cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Risk of cardiovascular events in men treated for prostate cancer compared with prostate cancer-free men

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Prostate Artery Embolization for Lower Urinary Tract Symptoms in Men Unfit for Surgery

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. 5hmC Level Predicts Biochemical Failure Following Radical Prostatectomy in Prostate Cancer Patients with ERG Negative Tumors

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Objective Primary androgen deprivation therapy (ADT) remains the gold standard in the management of patients with advanced prostate cancer (PCa). ADT relieves symptoms and reduces tumor burden, but it has never been demonstrated to increase either PCa-specific or overall survival per se. Several trials have challenged this dogma. The aim of this study was to evaluate how endocrine therapy (ET) affects survival in different clinical settings of PCa. Materials and methods A review of published phase II, III and IV studies evaluating the effect of ET on survival was performed. Results In localized and locally advanced non-metastatic PCa, neoadjuvant ET before radical prostatectomy has no effect on survival. Neoadjuvant and adjuvant ET in combination with curatively intended radiotherapy results in PCa-specific and overall survival benefit, although the duration of ET remains under debate. In N + disease, the timing of ET is under debate, although data suggest that early ET is associated with decreased PCa-specific and overall mortality. In M + disease, no proper randomized trials have been performed in patients with newly diagnosed M1 disease. In metastatic castration-resistant PCa, two novel endocrine agents have been proven to increase overall survival significantly compared to placebo. Conclusions ET has never been proven to increase survival in newly diagnosed metastatic PCa in a randomized clinical trial. Nonetheless, a number of trials supports that ET with proper timing, sequencing and in combination with other therapeutic modalities increases survival in several stages of PCa.

OriginalsprogEngelsk
TidsskriftScandinavian Journal of Urology and Nephrology
Vol/bind50
Udgave nummer3
Sider (fra-til)135-43
Antal sider9
ISSN0036-5599
DOI
StatusUdgivet - jun. 2016

ID: 46295562